Back to top
more

Horizon Pharma Public Limited Company (HZNP)

(Delayed Data from NSDQ)

$26.54 USD

26.54
1,058,972

+0.55 (2.12%)

Updated May 3, 2019 04:00 PM ET

After-Market: $26.52 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Ascendis' Dwarfism Candidate Gets Orphan Drug Status in EU

Ascendis' (ASND) TransCon CNP receives an Orphan Drug tag in Europe for the treatment of achondroplasia, the most common type of dwarfism.

Roche's Xolair sBLA for Self Administration Accepted by FDA

The FDA accepts Roche's (RHHBY) sBLA for a new self-administration option for Xolair across all approved U.S. indications.

Axsome's (AXSM) Earnings Beat in Q2, Pipeline Progresses

Axsome (AXSM) incurs a narrower loss in the second quarter of 2020. The company remains on track to submit the NDA for AXS-05 and AXS-07.

Reata (RETA) Q2 Earnings Top, Omaveloxolone Setback Hurts

Reata (RETA) gets FDA recommendation to initiate a second study on omaveloxolone for additional data.

Esperion (ESPR) Q2 Earnings Top, Drug Sales Hurt by Coronavirus

Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings and misses for sales.

AVEO Pharmaceuticals' (AVEO) Q2 Earnings Surpass Estimates

AVEO (AVEO) reports a narrower-than-expected loss but misses sales estimates in the second quarter of 2020.

Top Ranked Momentum Stocks to Buy for August 11th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 11th

Biohaven (BHVN) Q2 Earnings Beat on Strong Nurtec Uptake

Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, demonstrates strong launch uptake.

Iovance (IOVA) Q2 Earnings Beat Estimates, Pipeline in Focus

Iovance's (IOVA) second-quarter bottom line beats estimates. The company is progressing well with its lead pipeline candidates.

Horizon Therapeutics (HZNP) Looks Good: Stock Adds 5.3% in Session

Horizon Therapeutics (HZNP) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Puma's (PBYI) Earnings and Revenues Beat Estimates in Q2

Puma Biotech's (PBYI) bottom and the top line better estimates for the second quarter of 2020.

Clovis (CLVS) Q2 Earnings Lag, Revenues Show Coronavirus Impact

Clovis (CLVS) reports dismal second-quarter 2020 results. Sales of the company's sole marketed drug, Rubraca, decline sequentially. Shares down.

ACADIA (ACAD) Q2 Earnings Surpass, Nuplazid Drives Sales

ACADIA (ACAD) beats on earnings and revenues for the second quarter. The company lifts the lower end of its net sales view for Nuplazid, driving the stock in pre-market trading.

Horizon (HZNP) Q2 Earnings Down Y/Y, Tepezza Drives Sales

Horizon Therapeutics' (HZNP) earnings decline year over year and sales beat estimates in the second quarter of 2020.

Allogene's (ALLO) Q2 Loss Widens Y/Y, Pipeline Progresses

Allogene (ALLO) reports no revenues for the second quarter of 2020.

Sarepta (SRPT) Q2 Loss Widens Y/Y, Revenues Beat Estimates

Sarepta (SRPT) Q2 revenues increase year over year.

Arena Pharmaceuticals (ARNA) Q2 Loss Narrower Than Expected

Arena Pharmaceuticals (ARNA) beats bottom-line estimates for the second quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.

BioDelivery (BDSI) Q2 Earnings Miss, Revenues Beat, Stock Up

BioDelivery's (BDSI) strong Belubca sales drive the top line. Symproic further boosts revenues. Stock up.

Jazz Pharma (JAZZ) Beats on Q2 Earnings & Sales, Raises View

Jazz Pharmaceuticals (JAZZ) reports better-than-expected second-quarter 2020 earnings and revenues. It raises its guidance for 2020. Shares rise.

BioMarin (BMRN) Q2 Earnings Top, Sales Show Coronavirus Impact

BioMarin (BMRN) reports better-than-expected second-quarter results. The company maintains its previously issued guidance for 2020.

Amarin (AMRN) Beats on Q2 Earnings, Focuses on Europe

Amarin's (AMRN) revenue growth in the second quarter is attributable to continued demand for its cardiovascular drug, Vascepa.

Horizon Therapeutics (HZNP) Q2 Earnings and Revenues Top Estimates

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 7.50% and 26.67%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug/Biotech Stock Q2 Earnings on Aug 5: REGN, MRNA & More

Let us take a look at five drug/biotech companies, REGN, MRNA, SRPT, ACAD and HZNP, which are gearing up for their earnings release.

BMY vs. HZNP: Which Stock Should Value Investors Buy Now?

BMY vs. HZNP: Which Stock Is the Better Value Option?

Horizon Therapeutics (HZNP) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Horizon Therapeutics (HZNP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.